218 related articles for article (PubMed ID: 31907647)
1. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Wang Z; Gao J; Ohno Y; Liu H; Xu C
Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647
[TBL] [Abstract][Full Text] [Related]
2. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.
Wang Z; Gao J; Zhou J; Liu H; Xu C
J Gynecol Oncol; 2019 Mar; 30(2):e26. PubMed ID: 30740957
[TBL] [Abstract][Full Text] [Related]
3. [IL-1β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells].
Xu JF; Cen YX; Tang SS; Ren Y; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jul; 57(7):519-529. PubMed ID: 35902786
[No Abstract] [Full Text] [Related]
4. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence.
Luo H; Yount C; Lang H; Yang A; Riemer EC; Lyons K; Vanek KN; Silvestri GA; Schulte BA; Wang GY
Lung Cancer; 2013 Aug; 81(2):167-73. PubMed ID: 23683497
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
Zhong Q; Xiong Y; Ling C; Qian Y; Zhao X; Yang H
Exp Biol Med (Maywood); 2021 Jun; 246(11):1297-1306. PubMed ID: 34092127
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract][Full Text] [Related]
7. Identification of a pyridine derivative inducing senescence in ovarian cancer cell lines via P21 activation.
Shang D; Wu Y; Ding Y; Lu Z; Shen Y; Zhu F; Liu H; Zhu C; Tu Z
Clin Exp Pharmacol Physiol; 2018 May; 45(5):452-460. PubMed ID: 29143360
[TBL] [Abstract][Full Text] [Related]
8. Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis.
Wu Y; Wu T; Hu X; Xu S; Xiao D; Wu J; Yan X; Yang X; Li G
Int J Med Sci; 2022; 19(2):233-241. PubMed ID: 35165509
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
10. 1,25-Dihydroxyvitamin D exerts an antiaging role by activation of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling.
Chen L; Yang R; Qiao W; Zhang W; Chen J; Mao L; Goltzman D; Miao D
Aging Cell; 2019 Jun; 18(3):e12951. PubMed ID: 30907059
[TBL] [Abstract][Full Text] [Related]
11. Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro.
Uruski P; Sepetowska A; Konieczna C; Pakuła M; Wyrwa M; Tussupkaliyev A; Tykarski A; Mikuła-Pietrasik J; Książek K
Cell Mol Biol Lett; 2021 Oct; 26(1):44. PubMed ID: 34674640
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
13. Anti-oncogenic PTEN induces ovarian cancer cell senescence by targeting P21.
Ke X; Li L; Li J; Zheng M; Liu P
Cell Biol Int; 2022 Jan; 46(1):118-128. PubMed ID: 34643308
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
15. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
16. The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell.
Chen X; Chen Y; Lin X; Su S; Hou X; Zhang Q; Tian Y
Curr Pharm Biotechnol; 2018; 19(6):506-513. PubMed ID: 30003858
[TBL] [Abstract][Full Text] [Related]
17. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway.
Hu W; Li M; Chen Y; Gu X
J Ovarian Res; 2021 Sep; 14(1):121. PubMed ID: 34535173
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
Rytelewski M; Maleki Vareki S; Mangala LS; Romanow L; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Figueredo R; Ferguson PJ; Vincent M; Sood AK; Koropatnick JD
Oncotarget; 2016 Apr; 7(15):20825-39. PubMed ID: 26959114
[TBL] [Abstract][Full Text] [Related]
19. Guilu Erxian Glue () Inhibits Chemotherapy-Induced Bone Marrow Hematopoietic Stem Cell Senescence in Mice May via p16
Wang J; Ying YY; Chen ZH; Shao KD; Zhang WP; Lin SY
Chin J Integr Med; 2020 Nov; 26(11):819-824. PubMed ID: 32915425
[TBL] [Abstract][Full Text] [Related]
20. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
